Evidence map›Paper›PMID 28198733›Full record

ReviewCurrent opinion in nephrology and hypertension2017

Clinical relevance of sarcopenia in chronic kidney disease.

Ranjani N Moorthi, Keith G Avin

Open access · greenAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Current opinion in nephrology and hypertension, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 141 papers, 6 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
141citing papers in PubMed, 6 pooled it
12.1field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

141 citing papers in PubMed, 6 syntheses or guidelines pooled it, 259 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. The association between chronic kidney disease, falls, and fractures: a systematic review and meta-analysis.Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA · 2020
    Pooled it
  7. Trial
  8. Trial
  9. FGF23, Frailty, and Falls in SPRINT.Journal of the American Geriatrics Society · 2021
    Trial
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Bone Mineral Density and the Risk of Fracture According to eGFR in Postmenopausal Women.Journal of the American Society of Nephrology : JASN · 2026
    Article
  16. Article
  17. Cassandra's Cortex: The False Reassurance of a Normal T Score in CKD.Journal of the American Society of Nephrology : JASN · 2026
    Article
  18. Observational
  19. Article
  20. Article

81 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

2 authors at 2 institutions in 1 country.

Ranjani N MoorthiaDivision of Nephrology, Department of Medicine, Indiana University School of Medicine bDepartment of Physical Therapy, Indiana University, Indianapolis, Indiana, USA.
Keith G Avin
Indiana University – Purdue University Indianapolis · USIndiana University School of Medicine

Funding

Longitudinal Assessment of Skeletal Muscle Physiology in Dialysis PatientsK23DK102824 · NIDDK · INDIANA UNIVERSITY INDIANAPOLIS · PI MOORTHI, RANJANI N. · 2015 to 2019
$892k
Mechanisms of Interventions to Ameliorate Sarcopenia in Chronic Kidney DiseaseK08DK110429 · NIDDK · INDIANA UNIVERSITY INDIANAPOLIS · PI AVIN, KEITH G · 2016 to 2021
$718k
NIDDK NIH HHS K08 DK110429NIDDK NIH HHS K23 DK102824
6 · The paper itself

Abstract

purpose of reviewIn this article, we review sarcopenia in chronic kidney disease (CKD). We aim to present how definitions of sarcopenia from the general population may pertain to those with CKD, its assessment by clinicians and emerging therapies for sarcopenia in CKD. For this review, we limit our description and recommendations to patients with CKD who are not on dialysis. RECENT

findingsPoorer parameters of lean mass, strength and physical function are associated with worsening patient-centered outcomes such as limiting mobility, falls and mortality in CKD; however, the magnitude of these associations are different in those with and without CKD. Sarcopenia in CKD is a balance between skeletal muscle regeneration and catabolism, which are both altered in the uremic environment. Multiple pathways are involved in these derangements, which are briefly reviewed. Differences between commonly used terms cachexia, frailty, protein-energy wasting, dynapenia and sarcopenia are described. Therapeutic options in predialysis CKD are not well studied; therefore, we review exercise options and emerging pharmacological therapies. SUMMARY: Sarcopenia, now with its own International Classification of Diseases, 10th Revision (ICD-10) code, is of importance clinically and should be accounted for in research studies in patients with CKD. Multiple therapies for sarcopenia are in development and will hopefully be available for our patients in the future.

Indexed as

Terminology as TopicExerciseHumansMuscle, SkeletalRenal Insufficiency, ChronicSarcopenia

Identifiers

PMID28198733
PMCPMC5860815
OpenAlexW2588194504

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.